aTyr Pharma downgraded by Oppenheimer
$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Oppenheimer downgraded aTyr Pharma from Outperform to Perform
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/5/2023 | Outperform → Perform | Oppenheimer | |
11/11/2021 | $18.00 → $11.00 | Buy | HC Wainwright & Co. |
11/11/2021 | $18.00 → $11.00 | Action List Buy | HC Wainwright & Co. |
10/12/2021 | $22.00 | Outperform | RBC Capital |
9/21/2021 | $19.00 | Overweight | Piper Sandler |
9/14/2021 | $20.00 → $21.00 | Buy | Roth Capital |
9/14/2021 | $14.00 → $20.00 | Outperform | Oppenheimer |
9/13/2021 | $13.00 → $18.00 | Buy | HC Wainwright & Co. |